Focused On-demand Library for Alanyl-tRNA editing protein Aarsd1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9BTE6

UPID:

AASD1_HUMAN

Alternative names:

Alanyl-tRNA synthetase domain-containing protein 1

Alternative UPACC:

Q9BTE6; B4DI73

Background:

Alanyl-tRNA editing protein Aarsd1, also known as Alanyl-tRNA synthetase domain-containing protein 1, plays a crucial role in protein synthesis. It functions in trans to correct the amino acid moiety from incorrectly charged tRNA(Ala), ensuring the accuracy of protein translation. This process is vital for the proper functioning of cellular machinery.

Therapeutic significance:

Understanding the role of Alanyl-tRNA editing protein Aarsd1 could open doors to potential therapeutic strategies. Its precise function in amino acid correction highlights its importance in maintaining protein integrity, suggesting that modulation of its activity could have implications in diseases where protein synthesis is compromised.